Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.

Sechaud, Romain; Gu, Helen; Rahmanzadeh, Gholamreza; Taylor, Amanda; Chiparus, Ovidiu; Sharma, Gopal Krishna; Breitschaft, Astrid; Menssen, Hans D

Sechaud, Romain; Gu, Helen; Rahmanzadeh, Gholamreza; Taylor, Amanda; Chiparus, Ovidiu; Sharma, Gopal Krishna; Breitschaft, Astrid; Menssen, Hans D.

Afiliação

Sechaud R; Novartis Pharma AG, 4002, Basel, Switzerland. romain.sechaud@novartis.com.
Gu H; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Rahmanzadeh G; Novartis Pharma AG, 4002, Basel, Switzerland.
Taylor A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Chiparus O; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Sharma GK; Novartis Healthcare Pvt. Ltd., Hyderabad, Telangana, 50081, India.
Breitschaft A; Parexel International GmbH, 14059, Berlin, Germany.
Menssen HD; Novartis Pharma AG, 4002, Basel, Switzerland.

Cancer Chemother Pharmacol ; 2024 Mar 05.

Article em En | MEDLINE | ID: mdl-38438807

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article